Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03400787 · ClinicalTrials.gov registry record · NA

Latera RCT - Latera vs. Sham Control for Lateral Nasal Valve Collapse

A NA study of Nasal Valve Collapse and Nasal Breathing, sponsored by Spirox.

Completed
Registry status
NA
Development phase
137
Enrollment target
11
Study locations

NCT03400787 is a NA study of Nasal Valve Collapse and Nasal Breathing that has completed, run by Spirox. The registered enrollment target is 137 participants. The trial reports 11 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03400787, a NA study of Nasal Valve Collapse and Nasal Breathing, has completed, sponsored by Spirox.

COMPLETED
Registry status
NA
Development phase
137 participants
Enrollment target
11
Study locations

Study Summary

The primary objective of the LATERA RCT is to demonstrate the superiority of the Latera Implant to improve nasal breathing, compared with a Sham Control procedure.

Interventions

  • DEVICE Sham Procedure
  • DEVICE Latera Implant

Study Locations (11)

Texas

  • Texas ENT Specialist - Houston
  • ENT Associates of Texas - McKinney
  • Texas Facial Plastics and ENT - San Antonio

California

  • Sacramento ENT - Roseville
  • Breathe Clear Institute - Torrance

Georgia

  • ENT of GA - Atlanta

Illinois

  • Chicago Nasal and Sinus Center - Chicago

Indiana

  • Michiana Sleep and ENT Solutions - South Bend

New York

  • Albany ENT & Allergy - Albany

North Carolina

  • Piedmont ENT - Winston-Salem

Utah

  • Ogden Clinic - Ogden

Trial Details

FieldValue
Enrollment Target 137 participants
Start Date 2017-11-28
Est. Completion 2020-12-23
Phase NA

Sponsor

Spirox

3 total trials

What the Registry Record Tells You About NCT03400787

The ClinicalTrials.gov registry entry for NCT03400787 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spirox, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Nasal Valve Collapse appearing as the primary indexed condition, and to 2 interventions - of which Sham Procedure is the first listed.

NCT03400787 reports 11 study locations spanning 8 distinct geographic areas - top geographies include Texas, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT03400787 about?

NCT03400787 is a clinical study titled "Latera RCT - Latera vs. Sham Control for Lateral Nasal Valve Collapse". The primary objective of the LATERA RCT is to demonstrate the superiority of the Latera Implant to improve nasal breathing, compared with a Sham Control procedure.

What is the current status of trial NCT03400787?

This trial is currently completed. It is a NA study. The enrollment target is 137 participants. The study started on 2017-11-28. Estimated completion is 2020-12-23.

What conditions does trial NCT03400787 study?

This clinical trial studies the following conditions: Nasal Valve Collapse, Nasal Breathing.

What interventions are being tested in trial NCT03400787?

The interventions under investigation include: Sham Procedure (DEVICE), Latera Implant (DEVICE).

Who is sponsoring clinical trial NCT03400787?

This trial is sponsored by Spirox, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03400787 being conducted?

This trial has 11 study locations across California, Georgia, Illinois, Indiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Nasal Valve Collapse

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.